Q2 EPS Estimates for Henry Schein Reduced by Zacks Research

Henry Schein, Inc. (NASDAQ:HSIC - Free Report) - Research analysts at Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for shares of Henry Schein in a report released on Monday, May 26th. Zacks Research analyst R. Department now forecasts that the company will earn $1.16 per share for the quarter, down from their previous estimate of $1.19. The consensus estimate for Henry Schein's current full-year earnings is $4.74 per share. Zacks Research also issued estimates for Henry Schein's Q4 2025 earnings at $1.24 EPS, FY2025 earnings at $4.82 EPS, Q1 2026 earnings at $1.23 EPS, Q2 2026 earnings at $1.27 EPS, FY2026 earnings at $5.23 EPS and Q1 2027 earnings at $1.32 EPS.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.04. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. During the same period last year, the company earned $1.10 EPS. Henry Schein's revenue for the quarter was down .1% compared to the same quarter last year.

A number of other research firms have also recently commented on HSIC. Wells Fargo & Company lowered their target price on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Wall Street Zen cut Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. UBS Group lowered their target price on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research note on Wednesday, February 26th. Barrington Research lowered their target price on Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, Piper Sandler lowered their target price on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Henry Schein presently has an average rating of "Moderate Buy" and a consensus price target of $79.30.

Henry Schein Stock Down 2.9%

Shares of HSIC traded down $2.12 on Wednesday, reaching $69.86. The stock had a trading volume of 3,123,095 shares, compared to its average volume of 1,674,677. The firm has a market capitalization of $8.50 billion, a price-to-earnings ratio of 28.75, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The company has a 50-day simple moving average of $67.65 and a 200-day simple moving average of $71.63. Henry Schein has a 12-month low of $60.56 and a 12-month high of $82.49.

Insider Buying and Selling at Henry Schein

In related news, Director Philip A. Laskawy sold 2,604 shares of the business's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the transaction, the director now directly owns 24,805 shares in the company, valued at $1,762,147.20. The trade was a 9.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the business's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the transaction, the chief executive officer now owns 62,688 shares in the company, valued at approximately $4,460,251.20. This trade represents a 6.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new stake in Henry Schein during the 1st quarter valued at about $1,859,000. Acadian Asset Management LLC purchased a new stake in Henry Schein during the 1st quarter valued at about $676,000. IFM Investors Pty Ltd grew its stake in Henry Schein by 6.6% during the 1st quarter. IFM Investors Pty Ltd now owns 23,831 shares of the company's stock valued at $1,737,000 after purchasing an additional 1,482 shares during the last quarter. Focus Partners Wealth grew its stake in Henry Schein by 1.8% during the 1st quarter. Focus Partners Wealth now owns 32,241 shares of the company's stock valued at $2,208,000 after purchasing an additional 560 shares during the last quarter. Finally, Bayforest Capital Ltd purchased a new stake in Henry Schein during the 1st quarter valued at about $103,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.